Lung Transplant Failure Clinical Trial
— P-PODOfficial title:
Prone Positioning in Neurologically Deceased Potential Organ Donors to Improve Donor Lung Function and Lung Transplant Recipient Outcomes (P-POD) Pilot Trial
Verified date | May 2024 |
Source | University Health Network, Toronto |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the practicality of performing a future, large-scale study. The future study will look at the effect of mechanical ventilation in neurologically deceased (brain-dead) lung donors who are positioned to lay flat on their stomach (prone position), compared to donors who are positioned to lay flat on their back (supine position). The study will also look at the potential impact of prone positioning of the donor on transplant recipients of the study organs. The investigators are doing this study because the investigators want to increase the availability of donor lungs for lung transplant. Lung transplant is a life-saving treatment for individuals with lung disease, but there are not enough donated lungs to meet demand. Researchers are looking for better ways of preventing donated lungs from becoming unsuitable for transplant. Because of this, the goal of our study is to test whether prone positioning in neurologically deceased (brain-dead) lung donors can improve donor lung function and decrease complications, potentially increasing the number of donor lungs that can be used for transplant.
Status | Not yet recruiting |
Enrollment | 40 |
Est. completion date | August 1, 2026 |
Est. primary completion date | August 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age = 18 years 2. Neurological determination of death at time of study entry 3. Consent to organ donation 4. Eligible for organ donation as confirmed by Trillium Gift of Life Network Coordinator Exclusion Criteria: 1. Open chest or abdominal wounds on the ventral body surface 2. Absolute contraindication to lung transplantation on initial eligibility screening: - Infection i. Positive HIV, HbsAg, Human T-lymphotropic virus-I/II test results ii. Positive West Nile Virus (WNV PCR) test results iii. Rabies diagnosis or within the last 6 months bitten by an animal proven to have rabies iv. Active endocarditis v. Active encephalitis or meningitis of unknown etiology vi. Active disseminated tuberculosis vii. Viral hemorrhagic fever including Ebola or known exposure to person with Ebola viii. COVID-19 presumptive or confirmed positive in the last 14 days - Malignancy i. Donors with active cancer (donors receiving chemotherapy or radiation therapy or palliative cancer care within the last 5 years); excluding skin and primary brain tumors and prostate cancers. ii. Donors with a history of the following malignancies: - Lung Cancer - Choriocarcinoma - Breast Cancer - Colon Cancer within the last 10 years iii. Donors with active or past history of melanoma o Clinician decision that prone position is contraindicated |
Country | Name | City | State |
---|---|---|---|
Canada | Toronto General Hospital | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
Lorenzo delSorbo |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | This pilot randomized controlled trial will assess the feasibility of conducting a future full randomized clinical trial, specifically, to determine whether donor accrual will be adequate (if we recruit 40 donors from 4 sites over 1 year) | The number of donors enrolled into the trial over 1 year to be placed into either prone positioning or supine positioning prior to lung transplant | 90 days | |
Primary | To document adherence to the explicit prone positioning and mechanical ventilation protocol (if more than 80% of donors have no major protocol violations then considered adequate) | Number of major protocol violations, specifically:
Time from donation consent to randomization > 3 hours; Time from randomization to initiation of study assigned protocol > 3 hours; Time spent in prone positioning < 50% of the total time from study consent to study termination |
90 days | |
Primary | To document the number of those who cross over to the alternate strategy (if fewer than 10% of donors cross over to the alternate strategy, when not allowed by protocol then considered adequate) | The percentage of donors who cross over to the alternate strategy, when not allowed by protocol | 90 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05526950 -
Cytokine Filtration in Lung Transplantation: A Swedish National Study (GLUSorb)
|
N/A | |
Recruiting |
NCT06202859 -
Respiratory Physiotherapy as a Tool to Increase the Number of Solid Organ Donors
|
N/A | |
Completed |
NCT05242289 -
Cytokine Adsorption in Lung Transplantation
|
N/A | |
Recruiting |
NCT04837339 -
Diagnostic and Prognostic Biomarkers of Transplant Dysfunction in the Context of Lung Transplantation
|
N/A | |
Completed |
NCT03052153 -
Intraoperative Echocardiographic Evaluation of Pulmonary Vein Velocities and Outcomes in Lung Transplantation
|
||
Not yet recruiting |
NCT06399302 -
Prospective Multicenter Research on Donor and Recipient Management Strategies to Improve Lung Transplant Outcomes
|
||
Recruiting |
NCT06250517 -
Impact of the Ex-vivo Pulmonary Perfusion System on the Microbiome of Lung Grafts and Their Inflammatory Reaction.
|
N/A | |
Not yet recruiting |
NCT04146727 -
Utilizing Technology for Optimization of Pain Management and Mobilization in High Risk Cardiac Surgical ICU Patients
|
||
Recruiting |
NCT06125535 -
Biomolecular Phenotyping of Lung Transplant Recipients
|
||
Not yet recruiting |
NCT03089489 -
Lung PGD Biomarkers in Organ Donors
|
N/A |